Clinical Data Science GmbH, Basel, Switzerland.
University of South Florida Ataxia Research Center, Tampa, Florida.
Ann Clin Transl Neurol. 2020 Sep;7(9):1708-1712. doi: 10.1002/acn3.51118. Epub 2020 Aug 11.
The modified Friedreich Ataxia Rating Scale (mFARS) is a disease specific, exam-based neurological rating scale commonly used as a outcome measure in clinical trials. While extensive clinimetric testing indicates it's validity in measuring disease progression, formal test-retest reliability was lacking. To fill this gap, we acquired results from screening and baseline visits of several large clinical trials and calculated intraclass correlation coefficients, coefficients of variance, standard error, and the minimally detectable changes. This study demonstrated excellent test-retest reliability of the mFARS, and it's upright stability subscore.
改良的弗里德里希共济失调评定量表（mFARS）是一种特定于疾病的、基于检查的神经学评定量表，常用于临床试验中的结果测量。尽管广泛的临床计量学测试表明其在测量疾病进展方面的有效性，但正式的测试-再测试可靠性仍然缺乏。为了填补这一空白，我们从几项大型临床试验的筛选和基线访问中获取了结果，并计算了组内相关系数、变异系数、标准误差和最小可检测变化。这项研究表明，mFARS 及其直立稳定性子评分具有极好的测试-再测试可靠性。
